Skip to main content

Tempus xG

Tempus has launched a new germline sequencing assay, xG, a 52-gene panel that specifically identifies genetic variants associated with hereditary cancer syndromes and inherited risk of cancer. The test is performed by BioReference Laboratories' subsidiary GeneDx and joins Tempus' existing suite of oncology-focused testing offerings, including tumor and liquid biopsy tests, HRD, and TO (tumor of unknown origin) assays.